Frontage develops a full validation of the XTMAB-16 NAb (neutralizing antibody) assay with acceptable drug and target tolerances to guide future clinical trials.
Register to gain access to gated resources.
Thank you for registering!
You now have the option of downloading the resource or viewing the web version below.
Frontage introduces a new ultrasensitive assay for the quantitative determination of pTau217 in human plasma, serum, and cerebrospinal fluid (CSF), one of the most promising blood-based biomarkers of Alzheimer’s disease.
Frontage offers an impressive list of biomarker assays. Download our ever-growing list of biomarker assays to find what you need. Don't see what you're looking for? Contact us for your custom assay requests.
Frontage supports early drug discovery with various immunoassays for proteins and therapeutic antibodies to support pharmacokinetics/toxicokinetics (PK/TK), pharmacodynamics (PD), and biomarkers analysis.